Cantor Fitzgerald Reiterates Overweight on Pfizer, Maintains $45 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Pfizer, maintaining a price target of $45.
August 19, 2024 | 4:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Pfizer, maintaining a price target of $45, indicating confidence in the stock's potential.
The reiteration of an Overweight rating and a maintained price target of $45 by a reputable analyst suggests a positive outlook for Pfizer's stock. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100